\n
![](\"https:\/\/fortune.com\/img-assets\/wp-content\/uploads\/2024\/04\/GettyImages-1586473082-e1712970842222.jpg?w=2048\")
<\/p>\n [ad_1]
\n<\/p>\n
Drug regulators in Europe have found no evidence that popular diabetes and weight-loss drugs like Ozempic and Wegovy are linked to a higher risk of suicidal thoughts or actions.<\/p>\n
The European Medicines Agency regulatory committee announced the\u00a0results of its review<\/a>\u00a0on Friday. It\u2019s the latest group to conclude there\u2019s no known tie between a new class of obesity drugs and suicide.<\/p>\n In January, the U.S. Food and Drug Administration said a\u00a0preliminary review<\/a>\u00a0showed no evidence of such a link, though the agency said it could not rule out that \u201ca small risk may exist\u201d and that it would continue to study the issue. A\u00a0federally funded U.S. study<\/a>\u00a0also found that people taking semaglutide, the medication in Ozempic and Wegovy, had a lower risk of suicidal thoughts than those taking older medications to treat diabetes and obesity.<\/p>\n The review by the European Union\u2019s regulators was triggered last July by anecdotal reports that people taking the drugs had thoughts of self-harm. The regulators examined studies, post-marketing data and other research related to medications used in nearly a dozen drugs used to treat the diseases. The group did not review information regarding tirzepatide, the medication used in drugs sold as Mounjaro and Zepbound.<\/p>\n Both agencies said they would continue to closely monitor reports of suicidal thoughts or actions in people taking the drugs known as GLP-1 receptor agonists. Patients taking the drugs should report any mental health or other problems to their health care providers, officials said.<\/p>\n<\/div>\nSubscribe to Well Adjusted, our newsletter full of simple strategies to work smarter and live better, from the Fortune Well team. Sign up<\/a> for free today.<\/div>\n<\/div>\n